Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer

NCT07329894 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Cancer

Interventions

DRUG: XH001 injection
DRUG: Tumor vaccine-induced specific T-cell injection

Sponsor

Beijing GoBroad Hospital

Collaborators

[object Object]